Could SEG101 Revolutionize the Treatment for Sickle Cell Disease?
Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.
If LEE011 manages to demonstrate efficacy in difficult-to-treat cancer types, it could prove to be a major competitive advantage for Novartis.
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Novartis (NVS) has been striving to differentiate its investigational oncology drug, LEE011, from other breast cancer drugs in three areas.
Besides the concluded mammary oncology assessment of LEE011’s Efficacy and Safety-2 (or MONALEESA-2) trial, Novartis (NVS) is also exploring its investigational breast cancer therapy in other phase three trials.
To fully utilize its technology, Novartis (NVS) has been extensively upgrading its core systems.
Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.
To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.
Novartis’s research and development strategy is based on portfolio prioritization, introducing cost efficiencies, implementing breakthrough technologies, and introducing new management.
In 2016, the surgical business of Alcon, Novartis’s (NVS) Consumables segment, witnessed a solid demand trend.
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
Novartis (NVS) has identified its core business priorities and developed a capital allocation strategy to increase its overall shareholder value.
Novartis (NVS) has projected its 2017 revenue to be close to what it earned in 2016. The company also expects its core operating income to be flat or to fall in the single digits.
Besides focusing on research and development (or R&D) efforts, Novartis (NVS) is also aiming to revamp its commercial strategy in 2017.
By 2020, Novartis plans to launch biosimilars of five major biologic therapies, including AbbVie’s Humira, Amgen’s Neulasta, Johnson & Johnson’s Remicade, and Amgen’s Enbrel.
Novartis (NVS) has estimated that one in three individuals will be over 50 years of age by 2020.
To effectively capitalize on the growing demand for new drugs while controlling pricing risks, Novartis (NVS) plans to implement a multipronged strategy.
Despite patent expiries worth $2.4 billion, Novartis (NVS) managed to report a flat revenue performance in 2016.
Novartis (NVS) expects its Alcon business to report low-single-digit revenue growth in 2017.
Novartis (NVS) has managed to secure reimbursement in 17 countries in Europe.